Skip to main content

Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke



Microglia and CNS-infiltrating monocytes/macrophages (CNS-MPs) perform pro-inflammatory and protective anti-inflammatory functions following ischemic stroke. Selective inhibition of pro-inflammatory responses can be achieved by Kv1.3 channel blockade, resulting in a lower infarct size in the transient middle cerebral artery occlusion (tMCAO) model. Whether beneficial effects of Kv1.3 blockers are mediated by targeting microglia or CNS-infiltrating monocytes/macrophages remains unclear.


In the 30-min tMCAO mouse model, we profiled functional cell-surface Kv1.3 channels and phagocytic properties of acutely isolated CNS-MPs at various timepoints post-reperfusion. Kv1.3 channels were flow cytometrically detected using fluorescein-conjugated Kv1.3-binding peptide ShK-F6CA as well as by immunohistochemistry. Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) was performed to measure Kv1.3 (Kcna3) and Kir2.1 (Kcnj2) gene expression. Phagocytosis of 1-μm microspheres by acutely isolated CNS-MPs was measured by flow cytometry.


In flow cytometric assays, Kv1.3 channel expression by CD11b+ CNS-MPs was increased between 24 and 72 h post-tMCAO and decreased by 7 days post-tMCAO. Increased Kv1.3 expression was restricted to CD11b+CD45lowLy6clow (microglia) and CD11b+CD45highLy6Clow CNS-MPs but not CD11b+CD45highLy6chigh inflammatory monocytes/macrophages. In immunohistochemical studies, Kv1.3 protein expression was increased in Iba1+ microglia at 24-48 h post-tMCAO. No change in Kv1.3 mRNA in CNS-MPs was observed following tMCAO.


We conclude that resident microglia and a subset of CD45highLy6clow CNS-MPs are the likely cellular targets of Kv1.3 blockers and the delayed phase of neuroinflammation is the optimal therapeutic window for Kv1.3 blockade in ischemic stroke.


Ischemic stroke is a leading cause of mortality and disability, and there is an urgent need for therapies that can limit ischemic brain injury beyond the acute phase following ischemic stroke [1,2,3,4]. Neuroinflammation mediated by innate immune cells of the CNS (microglia and CNS-infiltrating macrophages collectively called CNS mononuclear phagocytes or CNS-MPs) comprises of complex pro-inflammatory responses that promote neuronal injury as well as anti-inflammatory/neuroprotective responses [3, 5]. Potentially protective anti-inflammatory CNS-MP phenotypes predominate in the first 1–2 days following ischemic injury whereas detrimental pro-inflammatory phenotypes increase after 48 h [6,7,8]. Identifying the key regulators of detrimental and protective CNS-MP responses can facilitate discovery of novel targets for ischemic stroke. The recently proven efficacy of endovascular thrombectomy for acute ischemic stroke has created exciting opportunities to translate neuro-immunomodulatory and neuroprotective strategies that target disease mechanisms beyond the acute phase [9, 10].

The diverse transcriptional profiles adopted by CNS-MPs have been recently revealed by transcriptomic studies which found an emergence of unique disease-associated microglial (DAM) profiles and downregulation of homeostatic genes in mouse models of chronic neuroinflammation, aging, and neurodegeneration [11,12,13]. More recently, we identified molecular heterogeneity within DAM which is comprised of independently regulated pro-inflammatory and anti-inflammatory DAM sub-profiles [13]. The potassium channel Kv1.3 was identified as a marker and regulator of pro-inflammatory DAM [13], and inhibition of Kv1.3 channels was found to be beneficial in Alzheimer’s disease models as well as in the transient middle cerebral artery occlusion (tMCAO) ischemic stroke model [13,14,15]. Although increased expression of Kv1.3 channels have been confirmed in acutely isolated CNS-MPs by electrophysiology, it is unclear whether microglia and/or CNS-infiltrating macrophages are the primary cell type with increased Kv1.3 channel expression [14].

We have applied a novel flow cytometric assay of functional cell-surface Kv1.3 channels coupled with parallel phagocytic profiling of acutely isolated CNS-MPs [16] at early and delayed timepoints following tMCAO, to define the temporal profiles of Kv1.3 channel expression within CNS-MP subsets.

Materials and methods


Fluorescein-conjugated ShK-F6CA was purchased from Peptides International (Louisville, KY) [17, 18]. Fluorophore-conjugated antibodies for flow cytometry were obtained from BD Biosciences (CD11b-APC-Cy7, CD45-PE-Cy7, CD45-FITC, Ly6c-PE) [13]. Polystyrene phycoerythrin-fluorescent 1-μm microspheres (Thermo Fisher #F13083) were used for phagocytosis assays [16]. Percoll was purchased from Sigma-Aldrich (#P1644).


Male C57BL/6 J mice (JAX 000664) aged 8–12 weeks were housed in the Department of Animal Resources at Emory University under standard conditions. Institutional Animal Care and Use Committee approval was obtained, and all in vivo studies were performed in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institute of Health, and in compliance with the ARRIVE guidelines.

Transient middle cerebral artery occlusion (tMCAO) model

After anesthesia (isoflurane) and exposure of the carotid artery, a 6-0 silk suture was advanced from the external carotid artery into the internal carotid artery until the origin of the middle cerebral artery on the ipsilateral side [19, 20]. The suture was then withdrawn after 30 min of cerebral ischemia. Laser Doppler flow was used to monitor cerebral perfusion at baseline, at time of MCAO, immediately after recanalization, and 5 min post-recanalization. Animals with > 75% decreased middle cerebral blood flow and > 75% reperfusion were included. In total, 32 mice were included for flow cytometric analyses (30 min: n = 8, 24 h: n = 7, 48 h: n = 8, 72 h: n = 4, 7 days: n = 5). Sham surgery controls were performed (n = 3 per condition). Transcranial Doppler flow data demonstrating effective MCAO and complete reperfusion for mice included in the study are shown in Additional file 1: Figure S1.

CNS-MP isolation

After tMCAO, mice were euthanized at 30 min, 24 h, 48 h, 72 h, and 7 days followed by cardiac perfusion. CNS-MPs were acutely isolated from ipsilateral and contralateral hemispheres using Percoll density (70%/35%) centrifugation as previously described [16, 18]. After myelin removal, mononuclear cells were re-suspended in saline or Trizol. From each hemisphere, half was used for RNA extraction and the other half was used for flow cytometry.

Flow cytometry

Functional cell-surface Kv1.3 channel expression in acutely isolated CNS-MPs was measured using a validated fluorescein-conjugated ShK-F6CA assay [13, 18, 21]. Cells were incubated with 10 nM ShK-F6CA along with fluorophore-conjugated CD11b (APC-Cy7), CD45 (PE-Cy7), and Ly6c (PE) antibodies for 30 min and then washed twice with cold PBS to remove any unbound antibodies. Compensation controls were run along with appropriate negative/isotype controls [18]. Live mononuclear cells were first gated based on forward and side scatter profiles, and then single cells were gated and then further gated for CD11b+ CNS-MPs. CD11b+ CNS-MPs were gated into CD45lowLy6clow, CD45highLy6clow, and CD45highLy6chigh subpopulations. Each CNS-MP subpopulation [22, 23] was evaluated for ShK-F6CA labeling.

Immunohistochemical studies

Following 30 min MCAO, mice were euthanized at 1 h, 24 h, and 48 h timepoints and brains were post-fixed in 4% PFA for 24 h, then transferred to 30% sucrose for another 24 h, and then sectioned (30 μm) and preserved in cryoprotectant solution. Free-floating sections were blocked with 10% horse serum for 1 h, then incubated with primary antibodies (anti-Kv1.3 mAb 1:100 UC Davis/NIH NeuroMab clone L23/27, anti-Tmem119 rabbit mAb 1:100 #ab209064, or anti- Iba1 rabbit mAb 1:300 #ab178846) at 4 °C overnight. Sections were then washed and incubated with fluorophore-conjugated secondary antibodies (1:500) for 30 min and then mounted on slides and dried. Hard-mounting medium (with DAPI-VectorLabs # H1500) was used to mount sections which were then imaged on an immunofluorescence microscope (Microscope: Olympus BX51 and camera: Olympus DP70) at 20× and 60× (oil immersion) magnifications. The ipsilateral (stroke) hemisphere was marked prior to sectioning. At least five fields in the peri-infarct region ipsilaterally and corresponding region on contralateral hemisphere were imaged per mouse (n = 2–3 mice per timepoint). All immunofluorescence images were processed using ImageJ software (version 1.52a).

Phagocytosis assay

Acutely isolated CNS-MPs were incubated with phycoerythrin (PE)-conjugated microspheres (1:100) at 37 °C for 30 min, washed, and labeled with fluorophore-conjugated anti-CD11b (APC-Cy7) and anti-CD45 (FITC) antibodies. Microsphere phagocytosis in CNS-MPs was assessed as the proportion of cells taking up > 1 microsphere as previously reported [16].

Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)

CNS-MP RNA extracted in Trizol was purified for qRT-PCR [18, 24]. RNA was reverse-transcribed to cDNA (Ambion), and qRT-PCR was performed (7500 Fast RT-PCR instrument, Applied Biosystems) using cDNA, TaqMan PCR Master Mix and gene-specific TaqMan probes (Applied Biosystems) against Kcna3 (Mm00434599_s1), Kcnj2 (m00434616_m1), Ptgs2 (Mm00478374_m1), and Hprt (Mm03024075_m1) in duplicate. Relative gene expression was normalized to Hprt and calculated using the 2ΔΔCT method [25].

Statistical considerations

GraphPad Prism version 7.0 and SPSS Version 24 were used for statistical analyses. Pairwise comparisons were performed using T-tests (independent sample, two-tailed, unequal variance). Non-parametric Mann-Whitney U test was used for pairwise comparisons of flow cytometric data. The statistical significance level was set at p < 0.05.


CNS infiltration by peripherally derived monocytes/macrophages at 48–72 h post-tMCAO

Effective MCAO (18% baseline) and effective reperfusion (108% of baseline) were achieved in our 30-min tMCAO model (Additional file 1: Figure S1a). At 24 h, 2,3,5-triphenyltetrazolium chloride (TTC) staining demonstrated cerebral infarction as expected in the ipsilateral hemisphere (Additional file 1: Figure S1b). We characterized CD11b+ CNS-MPs in the ipsilateral and contralateral hemispheres (excluding the cerebellum) following tMCAO at 30 min to 7 days timepoints (Fig. 1a). As compared to 30 min following tMCAO, we observed a significant increase in the proportions of CD11b+CD45high CNS-MPs at 48 h (p = 0.02), 72 h (p = 0.00014), and 7 days (p < 0.00001) following tMCAO in the ipsilateral hemisphere but not in the contralateral hemisphere (Fig. 1b and Additional file 2: Figure S2a). Among all CD11b+ CNS-MPs, we also observed a significant increase in the proportions of CD45highLy6chigh CNS-infiltrating macrophages/inflammatory monocytes at 48 h (p = 0.023) and 72 h (p = 0.01) following tMCAO, and in proportions of CD11b+CD45highLy6clow non-inflammatory monocytes/activated microglia at 48 h to 7 days (p = 0.04) ipsilaterally following tMCAO [26, 27] (Fig. 1c). As compared to CD45highLy6clow CNS-MPs, the increase in proportions of CD45highLy6chigh CNS-MPs post-tMCAO was more robust (Fig. 1c). No changes in CNS-MP subset proportions were observed on the contralateral side. There was also an early increase in CNS CD11bnegCD45high lymphocytes ipsilaterally at 30 min which rapidly decreased by 24 h (Additional file 2: Figure S2b). These data confirm that a wave of CNS infiltration by inflammatory monocytes occurs between 48 h to 7 days post-tMCAO [26, 27].

Fig. 1
figure 1

Flow cytometric characterization of populations of CNS immune cells in the tMCAO model. a Experimental design and flow cytometric gating strategy: Following tMCAO, CNS-MPs were acutely isolated at 30 min, 24 h, 48 h, 72 h, and 7 days timepoints and characterized by flow-cytometry based on CD11b, CD45, and Ly6c expression. In independent experiments with viability indicators, viability of > 99% was confirmed using this gating strategy. b Comparison of CD45high cells within CD11b+ CNS-MPs. Quantitative analysis is shown on the right. c Subpopulations of CD11b+ CNS-MPs based on CD45 and Ly6c expression and temporal patterns post-tMCAO. An example of CD11b+ subpopulations from the ischemic hemisphere at 72 h post-tMCAO is shown on the left. Quantitative analysis of relative proportions of Ly6chigh and Ly6clow subsets of CD11b+CD45high cells in ipsilateral and contralateral hemispheres at various timepoints is shown. N = 4–8 mice/group, error bars represent standard error of mean. *indicates comparisons between hemispheres (*p < 0.05, **p < 0.01, ***p < 0.005). #indicates comparisons within ipsilateral hemispheres across timepoints using 30 min timepoint as reference (#p < 0.05, ##p < 0.01, ###p < 0.005)

Temporal flow cytometric profiling of Kv1.3 channels in CNS-MPs following tMCAO

We applied a flow cytometric assay of functional cell-surface Kv1.3 channels (ShK-F6CA) to describe the temporal profiles of Kv1.3 expression following tMCAO and identify the CNS-MP subsets with highest Kv1.3 channel expression (Fig. 2a) [13, 18, 21]. ShK-F6CA is a selective and highly potent peptide blocker of the Kv1.3 channel pore which requires the tetramerization of four Kv1.3 monomers. Unlike most traditional flow cytometric probes which recognize epitopes on proteins, ShK-F6CA binds only to functional Kv1.3 channels that are expressed on the cell surface and we and others have validated this approach to accurately measure Kv1.3 expression in acutely isolated CNS-MPs [13, 18, 21, 28]. We observed a robust and gradual ipsilateral increase in ShK-F6CA fluorescence labeling of Kv1.3 channels in CD11b+ CNS-MPs at 24 h (p = 0.017), 48 h (p = 0.009), and 72 h (p < 0.0001) post-tMCAO that nearly resolved by 7 days post-tMCAO (Fig. 2b, c). Minimal ShK-F6CA fluorescence was observed in CD11b+ CNS-MPs from the contralateral hemisphere (Fig. 2b, c). Among CD11b+ CNS-MP subsets (gating shown in Fig. 2a), we observed that Kv1.3 channels were increased ipsilaterally in CD11b+CD45lowLy6clow resident microglia (24 h p = 0.013, 48 h p = 0.009, 72 h p < 0.0001) and in CD11b+CD45highLy6clow CNS-MPs (24 h p = 0.049, 48 h p = 0.0005, 72 h p = 0.012, 7 days p = 0.05) (Fig. 2d, e). However, no significant changes in ipsilateral Kv1.3 expression were observed in CD11b+CD45highLy6chigh CNS-infiltrating macrophages/inflammatory monocytes following tMCAO (Fig. 2d, e) [26]. ShK-F6CA fluorescence in CD11b+CD45high splenic monocytes/macrophages was negligible following sham surgery or post-tMCAO (Additional file 3: Figure S3) suggesting that these subtypes express minimal functional Kv1.3 channels.

Fig. 2
figure 2

Temporal profiling of functional cell-surface Kv1.3 channels in CNS-MPs following tMCAO. a CNS-MPs following tMCAO were incubated with 100 nM ShK-F6CA along with flow cytometric antibodies. b Kv1.3 channel expression by CD11b+ CNS-MPs (one example from each timepoint) post-tMCAO. Negative control labeled with non-specific FITC-conjugated IgG. c Quantitative analysis of Kv1.3 channel expression by CD11b+ CNS-MPs at different timepoints following tMCAO. d Representative flow cytometric histograms showing distinct Kv1.3 surface expression in CD11b+CD45low and both Ly6low and Ly6chigh subsets of CD11b+CD45high cells. e Quantitative comparison of Kv1.3 channel expression by distinct CNS-MP subsets following tMCAO. N = 4–8 mice/group. Error bars represent standard error of mean. *indicates comparisons between hemispheres (* p < 0.05, **p < 0.01, ***p < 0.005). #indicates comparisons within ipsilateral hemispheres across timepoints using 30 min timepoint as reference (#p < 0.05, ##p < 0.01, ###p < 0.005)

Immunohistochemical validation of increased Kv1.3 protein expression following tMCAO

To validate our flow cytometric findings, we performed immunofluorescence imaging to characterize Kv1.3 channel protein expression in the brain at 1 h, 24 h, and 48 h following tMCAO (Fig. 3 and Additional file 4: Figure S4). We observed a change in microglial morphology from a ramified state to a more rounded, ameboid, and activated morphology in the ipsilateral hemisphere following tMCAO at 24 and 48 h timepoints (Fig. 3a). At 1 h post-tMCAO, minimal Kv1.3 immunoreactivity was noted in both ipsilateral and contralateral hemispheres and very low-level Kv1.3 positivity was observed in microglia (Additional file 4: Figure S4). At 24 h and 48 h post-tMCAO, we observed increased Kv1.3 immunoreactivity in Iba1+ CNS-MPs in the peri-infarct regions (Fig. 3a). We also performed immunofluorescence imaging to measure Kv1.3 expression and Tmem119 post-tMCAO to confirm microglial specificity of Kv1.3 expression (Fig. 3b). At 1 h post-MCAO, Tmem119 immunoreactive microglia exhibited an expected ramified morphology and low levels of Kv1.3 protein expression. At 48 h post-tMCAO, we observed a dramatic decrease in Tmem119 immunoreactivity indicating downregulation of Tmem119 (Fig. 3b). These findings are consistent with downregulation of homeostatic genes/proteins such as Tmem119 [11, 13] following ischemic injury. Based on our flow cytometric and immunohistochemical results as well as the recently published efficacy of selective Kv1.3 channel blockers in the MCAO mouse model [14], the pattern of functional Kv1.3 channel expression following tMCAO indicates that microglia that highly express Kv1.3 channels at 24–72 h post-tMCAO, but not infiltrating monocytes/macrophages, are likely to be the targets of Kv1.3-blocking therapies in stroke.

Fig. 3
figure 3

Immunohistochemical validation of increased Kv1.3 protein expression in microglia following tMCAO. a Immunofluorescence micrographs from tMCAO brain sections (48 h post-tMCAO) showing microglia/macrophage marker Iba1 (red) as well as Kv1.3 channel expression (green). Minimal Kv1.3 immunoreactivity was noted in the contralateral hemisphere while Kv1.3 positive Iba1+ microglia were seen in the peri-infarct region in the ipsilateral hemisphere. Co-localization between Iba1 and Kv1.3 is shown in yellow in the merged image. High-power (60×) images are shown on the right. Red—Iba1; green—Kv1.3; blue—DAPI. Also see Additional file 4: Figure S4 for related imaging from other timepoints. b Immunofluorescence micrographs from tMCAO brain sections (48 h post-tMCAO) showing abundant Tmem119 expression by ramified microglia in contralateral hemisphere while ipsilateral Tmem119 expression is significantly reduced. Decreased Tmem119 expression was associated with increased Kv1.3 expression. Co-localization between Iba1 and Kv1.3 is shown in yellow in the merged image. High-power (60×) images are shown on the right. Red—Tmem119; green—Kv1.3; blue—DAPI

Transcriptional alterations in potassium channel genes following tMCAO

Since we observed significant alterations in functional Kv1.3 channel expression on the surface as well as at the protein level in microglia at 24–72 h following tMCAO, we determined whether changes in Kv1.3/Kcna3 gene expression in CNS-MPs can account for this increased functional channel expression. In qRT-PCR studies performed on acutely isolated CNS-MPs (≈ 60% CD11b+ CNS-MPs [28]) from ipsilateral and contralateral hemispheres following tMCAO, we observed no significant changes in Kcna3 (Kv1.3) mRNA expression in ipsilateral or contralateral hemispheres (Fig. 4a). Interestingly, we observed a significant downregulation in gene expression of an inward-rectifying K channel (Kir2.1/Kcnj2) in CNS-MPs from both ipsilateral (48 h p = 0.02, 72 h p = 0.004) and contralateral hemispheres (24 h p = 0.025, 72 h p = 0.03) post-tMCAO (Fig. 4b) [29]. Downregulation of Kir2.1/Kcnj2 was most pronounced in the ipsilateral hemisphere at 72 h post-tMCAO (p = 0.004, Fig. 4b). It has been previously reported that increased Kv1.3 channel expression in microglia that is induced by pro-inflammatory stimuli is associated with a reciprocal decrease in Kir2.1 channels while anti-inflammatory stimuli increase Kir2.1 currents [29]. Furthermore, Kv1.3 channels may represent regulators of pro-inflammatory microglial responses while Kir2.1 may regulate anti-inflammatory and protective responses [13, 28]. Based on the minimal changes in Kv1.3/Kcna3 mRNA levels in CNS-MPs following tMCAO, the observed robust changes in functional Kv1.3 channels in microglia post-tMCAO may indicate post-transcriptional regulation of Kv1.3 channels in microglia.

Fig. 4
figure 4

Kv1.3 and Kir2.1 potassium channel gene expression in CNS-MPs post-tMCAO. Comparison of Kv1.3 (a) and Kir2.1 (b) gene expression in CNS-MPs isolated from ipsilateral and contralateral hemispheres at different timepoints following tMCAO by qRT-PCR (Hprt used as housekeeping gene). N = 3 mice/group, error bars represent standard error of mean. *indicates comparisons between hemispheres (*p < 0.05, **p < 0.01, ***p < 0.005) at a particular timepoint. #indicates comparisons within ipsilateral or contralateral hemispheres across timepoints using 30 min timepoint as reference (#p < 0.05, ##p < 0.01, ###p < 0.005)

Characterization of phagocytic properties of CNS-MP subsets following tMCAO

Microglia and CNS-infiltrating macrophages are involved in phagocytic clearance following CNS injury [3, 30]. We recently showed that higher phagocytic activity is observed in CNS-MPs with higher Kv1.3 channel expression and that phagocytic properties can be augmented by Kv1.3 blockade [13, 28]. Therefore, we characterized the phagocytic capacity of acutely isolated CD11b+ CNS-MPs following tMCAO at various timepoints using a validated flow cytometric assay [16]. We observed that microsphere phagocytosis by CD11b+ CNS-MPs peaked at 48 h post-tMCAO in both ipsilateral (p = 0.008) and contralateral (p = 0.03) hemispheres although this augmentation was more pronounced in the ipsilateral hemisphere (Fig. 5). Among CNS-MP subsets, phagocytic augmentation was observed at 48 h in both CD45low and CD45high CNS-MPs although CD11b+CD45high cells were more avid phagocytosers at all timepoints. We also observed an augmentation of phagocytic activity, both ipsilaterally and contralaterally (Fig. 5c). There was no correlation between phagocytic activity and Kv1.3 channel expression in our study (Additional file 5: Figure S5). These results suggest that CNS-MPs globally augment phagocytic activity in the ischemic brain and CNS-MP phagocytic activity in the tMCAO model does not appear to be coupled to Kv1.3 channel expression.

Fig. 5
figure 5

Alterations in phagocytic capacity of CNS myeloid subpopulations following tMCAO. a Acutely isolated CNS-MPs were incubated with PE-conjugated microspheres and labeled with CD11b-APC-Cy7 and CD45-FITC antibodies. Uptake of > 1 microsphere (phagocytic index) was measured by flow cytometry. Typical phagocytic indices for all CD11b+ CNS myeloid cells as well as CD45low and CD45high subpopulations at 48 h post-tMCAO (ipsilateral hemisphere) are shown (right). b, c Results from comparison of phagocytic capacity of all CD11b+ CNS-MPs as well as CD45low and CD45high subpopulations in ipsilateral and contralateral hemispheres following tMCAO. For all analyses, n = 3–4 mice/group, error bars represent standard error of mean, *p < 0.05, **p < 0.01


Microglial activation and CNS infiltration by peripheral myeloid cells following ischemic stroke can impact infarct expansion, edema, and neuronal survival [31]. Disease-modifying roles for CNS-MPs in ischemic stroke are suggested by microglia depletion studies resulting in exacerbation of neuroinflammation and brain injury in focal ischemic stroke models [32]. In neurodegeneration, microglia progressively transition from homeostatic to DAM states [12, 33, 34] and within DAM, we have identified distinct pro-inflammatory and anti-inflammatory DAM sub-profiles with potentially opposing functional roles [9, 13]. Although the relevance of the homeostatic and DAM paradigm to ischemic stroke is unclear, anti-inflammatory CNS-MP phenotypes have been observed in the first 1–2 days after which pro-inflammatory phenotypes predominate in rodent MCAO models [7]. Therefore, selective neuro-immunomodulatory therapies for stroke are needed that inhibit pro-inflammatory CNS-MP responses and shift CNS-MPs towards protective anti-inflammatory and homeostatic states rather than non-specific anti-microglial strategies [6, 32, 35, 36].

The Kv1.3 potassium channel has been identified as a promising therapeutic target to inhibit pro-inflammatory CNS-MP responses in neurodegenerative disease [15, 24, 28] as well as ischemic stroke models [14], resulting in improved neuropathological outcomes. Kv1.3 is highly co-expressed with pro-inflammatory DAM genes (Il1b, Tlr2, Hif1a, Ptgs2) and is a key regulator of pro-inflammatory CNS-MP responses [13, 28, 29, 37]. Kv1.3 channels regulate membrane potential, calcium flux, immune signaling, and effector functions of effector memory T cells, memory B cells, and subsets of activated microglia and macrophages [38, 39]. Neuronal Kv1.3 expression is limited to olfactory and cortical neurons as hetero-tetramers with other Kv1-family channels while immune cells exclusively express the homo-tetrameric channel [38, 39]. This pattern of expression allows selective blockade of immune Kv1.3 channels by highly selective small molecule blockers (Pap1) and sea anemone toxin-based peptides (ShK analogs) without undesired off-target effects [40, 41]. An early phase study of Kv1.3 channel-blocking ShK analog (ShK-186/dalazatide) in humans has demonstrated safety, supported by multiple pre-clinical studies showing safety and efficacy of Kv1.3 blockers in models of systemic autoimmunity, obesity, CNS demyelinating disorders, and neurodegeneration [15, 18, 28, 42,43,44], suggesting that rapid translation of Kv1.3 blockers to ischemic stroke is feasible [45]. To further build on the pre-clinical rationale of Kv1.3 channel blockade as a therapeutic approach in ischemic stroke, the key CNS immune cells targeted by Kv1.3 blockers and the optimal therapeutic window for Kv1.3 blockers need to be determined.

We have utilized a rapid flow cytometric assay of functional cell-surface Kv1.3 channels [13, 18, 21] to phenotype acutely isolated CNS-MPs following tMCAO, and found that functional Kv1.3 channel expression is increased specifically in CD11b+CD45lowLy6clow resident microglia as well as in the subset of CD11b+CD45highLy6clow CNS-MPs, but not in CD11b+CD45highLy6chigh inflammatory monocytes. Therefore, it is highly likely that microglia are the primary cell types targeted by Kv1.3 blockers and that the beneficial effects of Kv1.3 blockers in stroke models  are unlikely to be mediated via modulation of peripheral immune responses. We also found increased Kv1.3 expression in the CD11b+CD45highLy6clow population of CNS-MPs which may represent an activated population of microglia or non-inflammatory patrolling monocytes that are recruited to the brain [26]. We also observed that not all microglia increase Kv1.3 expression, suggesting that additional immune sub-profiling of microglia may provide novel biological insights into the regulation and roles of Kv1.3 channel expression in microglial activation [46]. Increased functional cell-surface Kv1.3 channel expression at 48 h post-tMCAO was not accounted for by mRNA-level changes in Kv1.3, implicating post-transcriptional and post-translational processes in channel regulation in microglia [46]. However, this interpretation is limited by the large variance in our qRT-PCR data, insufficient mRNA yields from CNS-MP subsets and the use of all CNS-MPs (which contain 60% CD11b+ CNS-MPs), rather than enriched CD11b+ CNS-MPs within the scope of this study. Based on increased Kv1.3 channel expression between 24 and 72 h followed by a decrease by 7 days post-tMCAO, we also define the therapeutic window for Kv1.3 blockers as the subacute/delayed phase of ischemic stroke rather than hyper-acute/acute timeframes.

Our tMCAO studies were limited to 30 min of vessel occlusion followed by reperfusion. This model was specifically selected to minimize mortality observed with longer durations of occlusion especially beyond 48 h post-tMCAO. Although we did not characterize Kv1.3 channel expression by flow cytometry in longer MCAO models, other groups have shown in the 60-min MCAO model that Kv1.3 protein expression was indeed increased between day 2 and day 8 post-MCAO, suggesting that our findings regarding delayed Kv1.3 channel expression by microglia seems to be consistent regardless of the duration of vessel occlusion [14]. As compared to traditional electrophysiological methods such as a whole-cell patch clamp which has very limited sampling capabilities (< 40–50 cells per mouse), our flow cytometric approach to characterize Kv1.3 channel expression provides a rapid and comprehensive strategy which also allows us to assess Kv1.3 expression within CNS-MP subsets. Another interesting finding that we report is the downregulation of Tmem119 protein in microglia at 48 h post-tMCAO, which suggests that microglia downregulate homeostatic genes/proteins and may potentially transition towards activated phenotypes following MCAO [11,12,13, 28]. Whether these delayed activated phenotypes share any similarities with DAM phenotypes observed in neurodegeneration remains to be explored. We also did not note any relationship between phagocytic activity in CNS-MPs and Kv1.3 channel expression. The overall increase in phagocytic activity in both hemispheres at 48 h post-tMCAO may indicate a global response although the mechanisms or implications of this observation remain unexplored. Our results with phagocytic uptake of latex microspheres also do not necessarily reflect the ability of CNS-MPs to clear cellular debris in the ischemic core or to phagocytose healthy neuronal synapses as these processes involve specific receptors including complement receptors [3, 47]. Ongoing studies investigating specific mechanisms of phagocytosis in post-stroke CNS-MPs, as well as transcriptomic and proteomic efforts to characterize CNS-MPs in stroke models, will provide additional clarification.

From a clinical perspective, our findings in the transient 30-min MCAO model are relevant to acute large-vessel occlusion (LVO) stroke, which represent 25–40% of acute ischemic stroke [1, 48]. With the advent of mechanical thrombectomy as a highly effective reperfusion strategy, acute LVO stroke patients can be treated up to 24 h post-onset of stroke symptoms. However, nearly 50% of patients still suffer significant disability [9] and very few effective therapies exist beyond the 24-h window [10, 49]. Since reperfusion can be established in LVO patients, the stroke field is ideally poised to revisit neuroprotective and neuro-immunomodulatory strategies such as Kv1.3 blockade to target disease mechanisms most relevant in the post-acute phases of ischemic stroke.


We have shown that Kv1.3 channels are specifically and highly expressed by resident microglia and a subset of CD45highLy6clow CNS-MPs and are the likely cellular targets of Kv1.3 blockers. Furthermore, we suggest that the delayed phase of neuroinflammation is the optimal therapeutic window for Kv1.3 blockade in ischemic stroke.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.



Central nervous system mononuclear phagocytes


Disease-associated microglia


Voltage-gated potassium channel 1.3


Transient middle cerebral artery occlusion


  1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation. 2017;135:e146–603.

    Article  Google Scholar 

  2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.

    Article  CAS  Google Scholar 

  3. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796–808.

    Article  CAS  Google Scholar 

  4. Kim AS, Johnston SC. Temporal and geographic trends in the global stroke epidemic. Stroke. 2013;44:S123–5.

    Article  Google Scholar 

  5. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87:779–89.

    Article  CAS  Google Scholar 

  6. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43:3063–70.

    Article  CAS  Google Scholar 

  7. Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke. Int J Mol Sci. 2017;18.

    Article  Google Scholar 

  8. Frieler RA, Meng H, Duan SZ, Berger S, Schutz G, He Y, Xi G, Wang MM, Mortensen RM. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke. 2011;42:179–85.

    Article  Google Scholar 

  9. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461–553.

    Article  CAS  Google Scholar 

  10. Gladstone DJ, Black SE, Hakim AM, Heart, Stroke Foundation of Ontario Centre of Excellence in Stroke R. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33:2123–36.

    Article  Google Scholar 

  11. Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease Not Evident in Mouse Models. Cell Rep. 2018;22:832–47.

    Article  CAS  Google Scholar 

  12. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169:1276–1290 e1217.

    Article  CAS  Google Scholar 

  13. Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, Duong DM, Pennington MW, Lah JJ, Seyfried NT, Levey AI. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener. 2018;13:24.

    Article  Google Scholar 

  14. Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Ann Clin Transl Neurol. 2018;5:147–61.

    Article  CAS  Google Scholar 

  15. Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain. 2018;141:596–612.

    Article  Google Scholar 

  16. Rangaraju S, Raza SA, Li NX, Betarbet R, Dammer EB, Duong D, Lah JJ, Seyfried NT, Levey AI. Differential phagocytic properties of CD45(low) microglia and CD45(high) brain mononuclear phagocytes-activation and age-related effects. Front Immunol. 2018;9:405.

    Article  Google Scholar 

  17. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006;103:17414–9.

    Article  CAS  Google Scholar 

  18. Rangaraju S, Raza SA, Pennati A, Deng Q, Dammer EB, Duong D, Pennington MW, Tansey MG, Lah JJ, Betarbet R, et al. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. J Neuroinflammation. 2017;14:128.

    Article  Google Scholar 

  19. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.

    Article  CAS  Google Scholar 

  20. Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res. 1999;833:181–90.

    Article  CAS  Google Scholar 

  21. Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003;278:9928–37.

    Article  CAS  Google Scholar 

  22. Greter M, Lelios I, Croxford AL. Microglia versus myeloid cell nomenclature during brain inflammation. Front Immunol. 2015;6:249.

    Article  Google Scholar 

  23. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131–43.

    Article  CAS  Google Scholar 

  24. Rangaraju S, Gearing M, Jin LW, Levey A. Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease. J Alzheimers Dis. 2015;44:797–808.

    Article  CAS  Google Scholar 

  25. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.

    Article  CAS  Google Scholar 

  26. Benakis C, Garcia-Bonilla L, Iadecola C, Anrather J. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci. 2014;8:461.

    PubMed  Google Scholar 

  27. Gliem M, Mausberg AK, Lee JI, Simiantonakis I, van Rooijen N, Hartung HP, Jander S. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol. 2012;71:743–52.

    Article  CAS  Google Scholar 

  28. Rangaraju S, Dammer EB, Raza SA, Gao T, Xiao H, Betarbet R, Duong DM, Webster JA, Hales CM, Lah JJ, et al. Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer's disease-related proteins. Mol Neurodegener. 2018;13:34.

    Article  Google Scholar 

  29. Nguyen HM, Grossinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia. 2017;65:106–21.

    Article  Google Scholar 

  30. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest. 2012;122:1164–71.

    Article  CAS  Google Scholar 

  31. Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics. 2016;13:661–70.

    Article  CAS  Google Scholar 

  32. Jin WN, Shi SX, Li Z, Li M, Wood K, Gonzales RJ, Liu Q. Depletion of microglia exacerbates postischemic inflammation and brain injury. J Cereb Blood Flow Metab. 2017;37:2224–36.

    Article  CAS  Google Scholar 

  33. Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173:1073–81.

    Article  CAS  Google Scholar 

  34. Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in nurodegenerative diseases. Immunity. 2017;47:566–81 e569.

    Article  CAS  Google Scholar 

  35. Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu F. Regulation of microglial activation in stroke. Acta Pharmacol Sin. 2017;38:445–58.

    Article  CAS  Google Scholar 

  36. Lee Y, Lee SR, Choi SS, Yeo HG, Chang KT, Lee HJ. Therapeutically targeting neuroinflammation and microglia after acute ischemic stroke. Biomed Res Int. 2014;2014:297241.

    PubMed  PubMed Central  Google Scholar 

  37. Di Lucente J, Nguyen HM, Wulff H, Jin LW, Maezawa I. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. 2018;66:1881–95.

    Article  Google Scholar 

  38. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev. 2009;231:59–87.

    Article  CAS  Google Scholar 

  39. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annu Rev Immunol. 2015;33:291–353.

    Article  CAS  Google Scholar 

  40. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005;68:1254–70.

    Article  CAS  Google Scholar 

  41. Beeton C, Pennington MW, Norton RS. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011;10:313–21.

    Article  CAS  Google Scholar 

  42. Tarcha EJ, Olsen CM, Probst P, Peckham D, Munoz-Elias EJ, Kruger JG, Iadonato SP. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS One. 2017;12:e0180762.

    Article  Google Scholar 

  43. Rangaraju S, Chi V, Pennington MW, Chandy KG. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin Ther Targets. 2009;13:909–24.

    Article  CAS  Google Scholar 

  44. Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, et al. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. Proc Natl Acad Sci USA. 2013;110:E2239–48.

    Article  CAS  Google Scholar 

  45. Perez-Verdaguer M, Capera J, Serrano-Novillo C, Estadella I, Sastre D, Felipe A. The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies. Expert Opin Ther Targets. 2016;20:577–91.

    Article  CAS  Google Scholar 

  46. Perez-Garcia MT, Cidad P, Lopez-Lopez JR. The secret life of ion channels: Kv1.3 potassium channels and proliferation. Am J Physiol Cell Physiol. 2018;314:C27–42.

    Article  Google Scholar 

  47. Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system diseases. Molecular neurobiology. 2014;49:1422–34.

    Article  CAS  Google Scholar 

  48. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–31.

    Article  Google Scholar 

  49. Kaur H, Prakash A, Medhi B. Drug therapy in stroke: from preclinical to clinical studies. Pharmacology. 2013;92:324–34.

    Article  CAS  Google Scholar 

Download references


We thank Dr. Allan I. Levey for critically reading this manuscript.


This study was supported by Alzheimer’s Association AARG 37102 (S.R.), NIH K08-NS099474-1 (S.R.), NS-091201 (M.Y), NS-079331 (M.Y.), and VA MERIT Award IO1BX003441 (M.Y). This study was supported in part by the Emory Flow Cytometry Core (EFCC), one of the Emory Integrated Core Facilities (EICF) and is subsidized by the Emory University School of Medicine. Additional support was provided by the Georgia Clinical & Translational Science Alliance of the NIH under Award Number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIH.

Author information

Authors and Affiliations



SRan, SAR, TG, SRam, and MY are responsible for the conceptualization. SRan, SAR, TG, AT, SRam, HX, NN, LC, and MY are responsible for the methodology. SRan, SAR, TG, SRam, AT, and MY are responsible for the investigation. SRan, SAR, and TG are responsible for the methodology writing and original draft. SRan and MY are responsible for the writing the review and editing, funding acquisition, resources, and supervision. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Srikant Rangaraju.

Ethics declarations

Ethics approval and consent to participate

Institutional animal care and use committee (IACUC) approval was obtained prior to any animal work.

Consent for publication

All authors have approved of the contents of this manuscript and provided consent for publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional files

Additional file 1:

Figure S1. Confirmation of effective tMCAO and reperfusion in mice. (DOCX 503 kb)

Additional file 2:

Figure S2. Alterations in proportions of CD45high CNS-MP subsets following tMCAO. (DOCX 319 kb)

Additional file 3:

Figure S3. Minimal cell-surface Kv1.3 expression by splenic monocytes. (DOCX 475 kb)

Additional file 4:

Figure S4. Immunohistochemical validation of Kv1.3 protein expression by microglia following tMCAO (related to Fig. 3). (DOCX 3630 kb)

Additional file 5:

Figure S5. Correlation between functional Kv1.3 channel expression and phagocytic capacity for fluorescent microspheres in acutely isolated CNS-MPs following tMCAO. (DOCX 26 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, T., Raza, S.A., Ramesha, S. et al. Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke. J Neuroinflammation 16, 116 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: